Author Archives: Ana Pena, PhD

Janssen has asked the U.S. Food and Drug Administration (FDA) to allow Darzalex (daratumumab) to also be used in combination with Kyprolis (carfilzomib)…

The multiple myeloma therapy Velcade (bortezomib) can induce the formation of pro-inflammatory macrophages — a kind of white blood cell — that promote the growth of myeloma tumors, Israeli researchers found. The presence of such cells in the bone marrow could help explain why some myelomas…

A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side effect of immunomodulatory therapies (IMiD) for multiple myeloma. Researchers established the set of factors — based on a person’s age, race, and medical…

The candidate CAR-T cell therapy bb2121 showed a favorable safety profile and eliminated traces of cancer in nearly half of heavily pre-treated multiple myeloma patients included in a Phase 1 clinical trial, interim results show.

Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening in patients with multiple myeloma who have failed prior treatments, including Revlimid (lenalidomide), results from a pivotal clinical trial show. Building on this…

The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (bortezomib) and dexamethasone, for the treatment of some adult patients with multiple myeloma. Revlimid, combined with Velcade and dexamethasone (RVd), is now indicated for…

Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and demonstrated promising signs of high efficacy in two global clinical trials conducted by Oncopeptides. The data was…

A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma, may also be effective and safe as a first-line treatment for newly diagnosed patients, according to a study. The dual combo yielded the…

The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed or refractory…

A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed or refractory multiple myeloma in a small Phase 1/2a pilot trial.  The agent was able to trigger myeloma cell death and halt cancer progression in two out…